Main Session
Sep
29
QP 03 - Right Care, Right Cost: Access and Utilization in Oncology
1012 - The Cost Effectiveness of Neoadjuvant FOLFIRINOX vs. Gemcitabine Based Chemoradiotherapy (CRT) for Resectable or Borderline-Resectable Pancreatic Ductal Adenocarcinoma
Presenter(s)
Nandita Kasireddy, BA - Geisel School of Medicine at Dartmouth, Lebanon, WA